Shopping spree at Eli Lilly? The US pharma giant is acquiring no fewer than three companies, all active in infectious diseases. Among them is Swiss biotech LimmaTech Biologics AG, led by former CureVac CEO Franz-Werner Haas. Yet Lilly’s ambitions extend well beyond classical infectious disease markets, targeting areas ranging from autoimmune disorders and antimicrobial resistance to chronic immune dysfunction and even cancer.
MS expert takes the helm
AppointmentsErik Lundgren assumed his role as the new CEO of Immunic. He succeeds Dr Daniel Vitt, who will continue to oversee the biotech company’s scientific strategy.
Standing Together in Uncertain Times
Sponsored PublicationsChemspec Europe returned to Cologne between 6-7 May 2026, drawing 4,238 attendees from 60 nations and 454 exhibitors from 28 countries, an increase from last year’s event.
OSE Immunotherapeutics turns to IRIS for €19.3m bridge financing
Latest NewsFrench immunotherapy developer OSE Immunotherapeutics has signed a term sheet for a flexible bridge equity financing with IRIS Capital Investment, giving the Nantes- and Paris-based biotech access to up to €19.3m in gross proceeds over 24 months.
Extra boost for Nuclidium: financing round reaches €115 million
Latest NewsBasel-based Nuclidium AG has secured an additional tranche for its ongoing Series B financing round, bringing the total to approximately €115 million. The theranostics company is developing copper-based radiopharmaceuticals that are used both for diagnostic imaging and therapeutic applications.
GSK reports 19% functional cure rate for near-approval hepatitis B drug
Latest NewsGSK has linked its chronic hepatitis B drug candidate to a 19% functional cure rate across a pair of Phase III trials, clearing the bar it set for clinical relevance.
Hansa data supports full approval plan for Idefirix
Latest NewsSwedish rare immunology specialist Hansa Biopharma AB has reported positive topline results from a European post-authorisation efficacy study of Idefirix, strengthening its case to convert the kidney transplant drug’s conditional EU approval into full marketing authorisation.
Ex-Palantir execs raise $12M to develop AI operating system at Perceptic
Latest NewsPerceptic has raised a $12 million (€10.3 million) seed round to advance an AI operating system used by companies including CSL.
Adcendo inks MSD supply deal to run ADC-Keytruda combination study
Latest NewsAdcendo has struck a Keytruda supply agreement with MSD, positioning the Danish biotech to study an antibody-drug conjugate (ADC) with the blockbuster checkpoint inhibitor.
Three in One Go: LimmaTech, Curevo, Vaccine Company
Latest NewsShopping spree at Eli Lilly? The US pharma giant is acquiring no fewer than three companies, all active in infectious diseases. Among them is Swiss biotech LimmaTech Biologics AG, led by former CureVac CEO Franz-Werner Haas. Yet Lilly’s ambitions extend well beyond classical infectious disease markets, targeting areas ranging from autoimmune disorders and antimicrobial resistance to chronic immune dysfunction and even cancer.
The European CDMO Model, Powering Biologics Innovation
Sponsored PublicationsEurope continues to play a pivotal role in the global biologics landscape, combining scientific excellence, regulatory maturity and a strong industrial foundation.